Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tam

Showing results (801-810 of 922) with videos related to

Pageof 93
Sort By:
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Nature|May 15, 2020
Infection of dogs with SARS-CoV-2Thomas H C Sit, Christopher J Brackman, Sin Ming Ip, et al.
Emerging Infectious Diseases|June 18, 2004
Laboratory diagnosis of SARSPaul K S Chan, Wing-Kin To, King-Cheung Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Environmental Pollution (Barking, Essex : 1987)|June 24, 2014
Exposure to air pollutants and mortality in hypertensive patients according to demography: a 10 year case-crossover studyMartin C S Wong, Wilson W S Tam, Harry H X Wang, et al.
Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Clinical & Experimental Ophthalmology|March 13, 2020
Association of the CAV1-CAV2 locus with normal-tension glaucoma in Chinese and JapaneseShi Yao Lu, Shi Song Rong, Zhenggen Wu, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Pageof 93

Showing results (801-810 of 922) with videos related to

Sort By:
Pageof 93
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Nature|May 15, 2020
Infection of dogs with SARS-CoV-2Thomas H C Sit, Christopher J Brackman, Sin Ming Ip, et al.
Emerging Infectious Diseases|June 18, 2004
Laboratory diagnosis of SARSPaul K S Chan, Wing-Kin To, King-Cheung Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Environmental Pollution (Barking, Essex : 1987)|June 24, 2014
Exposure to air pollutants and mortality in hypertensive patients according to demography: a 10 year case-crossover studyMartin C S Wong, Wilson W S Tam, Harry H X Wang, et al.
Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Clinical & Experimental Ophthalmology|March 13, 2020
Association of the CAV1-CAV2 locus with normal-tension glaucoma in Chinese and JapaneseShi Yao Lu, Shi Song Rong, Zhenggen Wu, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Pageof 93